ECSP088910A - Compuestos de pirrolo-pirimidina y sus usos - Google Patents
Compuestos de pirrolo-pirimidina y sus usosInfo
- Publication number
- ECSP088910A ECSP088910A EC2008008910A ECSP088910A ECSP088910A EC SP088910 A ECSP088910 A EC SP088910A EC 2008008910 A EC2008008910 A EC 2008008910A EC SP088910 A ECSP088910 A EC SP088910A EC SP088910 A ECSP088910 A EC SP088910A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirrolo
- pyrimidine compounds
- useful
- treatment
- organic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
Abstract
p La presente solicitud describe compuestos orgánicos que son útiles para el tratamiento, la prevención, y/o el alivio de enfermedades; en particular se describen compuestos de pirrolo-pirimidina y sus derivados, que inhiben a las cinasas de proteína. Los compuestos orgánicos son útiles en el tratamiento de enfermedades proliferativas
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80860506P | 2006-05-26 | 2006-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088910A true ECSP088910A (es) | 2008-12-30 |
Family
ID=38779335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008910A ECSP088910A (es) | 2006-05-26 | 2008-11-26 | Compuestos de pirrolo-pirimidina y sus usos |
Country Status (38)
Country | Link |
---|---|
US (2) | US8324225B2 (es) |
EP (1) | EP2029145B1 (es) |
JP (2) | JP2009538341A (es) |
KR (1) | KR101466412B1 (es) |
CN (1) | CN101594871B (es) |
AR (2) | AR061124A1 (es) |
AU (1) | AU2007267645C1 (es) |
BR (1) | BRPI0712816B8 (es) |
CA (1) | CA2652044C (es) |
CL (1) | CL2007001504A1 (es) |
CR (1) | CR10433A (es) |
CU (1) | CU23831B1 (es) |
EA (1) | EA016301B1 (es) |
EC (1) | ECSP088910A (es) |
ES (1) | ES2623133T3 (es) |
GE (1) | GEP20115283B (es) |
GT (1) | GT200800258A (es) |
HN (1) | HN2008001752A (es) |
HR (1) | HRP20170631T1 (es) |
IL (1) | IL195086A (es) |
JO (1) | JO3235B1 (es) |
MA (1) | MA30557B1 (es) |
ME (1) | ME00486B (es) |
MX (1) | MX2008015076A (es) |
MY (1) | MY150650A (es) |
NO (1) | NO343182B1 (es) |
NZ (1) | NZ572549A (es) |
PE (1) | PE20080263A1 (es) |
PL (1) | PL2029145T3 (es) |
PT (1) | PT2029145T (es) |
SG (1) | SG172632A1 (es) |
SM (1) | SMP200800069B (es) |
TN (1) | TNSN08481A1 (es) |
TW (1) | TWI398252B (es) |
UA (1) | UA95632C2 (es) |
UY (1) | UY30369A1 (es) |
WO (1) | WO2007140222A2 (es) |
ZA (1) | ZA200809382B (es) |
Families Citing this family (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2474545T3 (pl) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
PL2173752T5 (pl) | 2007-06-13 | 2022-12-05 | Incyte Holdings Corporation | Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej |
KR20100057650A (ko) * | 2007-08-23 | 2010-05-31 | 아스트라제네카 아베 | 증식성 질환의 치료를 위한 ttk/mps1의 억제제로서 2-아닐리노푸린-8-온 |
BRPI0821209A2 (pt) * | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
MX2010008719A (es) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. |
AR071645A1 (es) * | 2008-03-03 | 2010-07-07 | Takeda Pharmaceutical | Farmaco combinado |
ATE531372T1 (de) * | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
TW201002713A (en) * | 2008-04-09 | 2010-01-16 | Organon Nv | Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors |
JP2011518841A (ja) * | 2008-04-24 | 2011-06-30 | ニューリンク ジェネティクス, インコーポレイテッド | Ido阻害剤 |
WO2009152027A1 (en) * | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
WO2010045451A1 (en) * | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
EP3718560A3 (en) | 2009-05-13 | 2020-12-09 | The University of North Carolina at Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
TWI478714B (zh) | 2009-10-29 | 2015-04-01 | Vectura Ltd | 作為Janus激酶3(JAK3)抑制劑之含氮雜芳基衍生物類 |
WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
SG10202012179RA (en) | 2010-02-11 | 2021-01-28 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
TWI643857B (zh) | 2010-03-10 | 2018-12-11 | 英塞特公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
CA2800327A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
CA2961937C (en) * | 2010-10-25 | 2018-09-25 | G1 Therapeutics, Inc. | Cdk inhibitors |
US20120115878A1 (en) * | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
AU2011329763A1 (en) | 2010-11-17 | 2013-05-09 | Brigham And Women's Hospital | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
UA113156C2 (xx) | 2010-11-19 | 2016-12-26 | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
AU2012216893B2 (en) | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
KR20160035613A (ko) | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
US9187487B2 (en) * | 2011-05-17 | 2015-11-17 | Principia Biopharma, Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
KR20140040769A (ko) | 2011-07-01 | 2014-04-03 | 노파르티스 아게 | 조합 요법 |
JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法 |
EA201490229A1 (ru) | 2011-07-08 | 2014-05-30 | Новартис Аг | Новые пирролопиримидиновые производные |
WO2013017479A1 (en) * | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) * | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CN103958510B (zh) | 2011-10-03 | 2016-10-19 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的吡咯并嘧啶化合物 |
WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
IN2014DN09610A (es) | 2012-05-22 | 2015-07-31 | Univ North Carolina | |
WO2013188184A1 (en) * | 2012-06-14 | 2013-12-19 | Eli Lilly And Company | Inhibitor of jak1 and jak2 |
EP4119676A1 (en) | 2012-08-03 | 2023-01-18 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
IN2015DN02008A (es) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤 |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
PE20200175A1 (es) | 2012-11-15 | 2020-01-24 | Incyte Holdings Corp | Formas de dosificacion de ruxolitinib de liberacion sostenida |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
EP2934515B1 (en) * | 2012-12-20 | 2018-04-04 | Novartis AG | A pharmaceutical combination comprising binimetinib |
WO2014130693A1 (en) * | 2013-02-25 | 2014-08-28 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CN105143463A (zh) | 2013-02-25 | 2015-12-09 | 诺华股份有限公司 | 新的雄激素受体突变 |
EP2964648B1 (en) * | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
SI3489239T1 (sl) | 2013-03-06 | 2022-04-29 | Incyte Holdings Corporation | Postopki in intermediati za pripravo zaviralca JAK |
EP2976106B1 (en) | 2013-03-21 | 2021-04-14 | Array BioPharma Inc. | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
ES2782003T3 (es) | 2013-04-16 | 2020-09-09 | Memorial Sloan Kettering Cancer Center | Compañero de diagnóstico para inhibidores de CDK4 |
PT2989106T (pt) | 2013-04-25 | 2017-03-15 | Beigene Ltd | Compostos heterocíclicos fundidos como inibidores da proteína quinase |
US8895611B1 (en) | 2013-07-17 | 2014-11-25 | King Fahd University Of Petroleum And Minerals | Cytotoxic compounds for treating cancer |
SG10201912203XA (en) | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
CN103408546A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 2-苯氨基嘌呤类plk1抑制剂及其用途 |
EP3702373B9 (en) | 2013-09-13 | 2022-11-23 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
AU2015238305B2 (en) | 2014-03-26 | 2020-06-18 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
SI3122358T1 (sl) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka |
US9649309B2 (en) | 2014-04-11 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity |
US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JP2017516855A (ja) * | 2014-05-28 | 2017-06-22 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | 特定のタンパク質キナーゼ阻害剤 |
ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
SG10202004716RA (en) | 2014-07-24 | 2020-06-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
SI3204386T1 (sl) | 2014-10-06 | 2021-08-31 | Signal Pharmaceuticals, Llc | Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi |
AU2015333689A1 (en) | 2014-10-14 | 2017-05-25 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
CN105111215B (zh) * | 2014-12-12 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法 |
CN104610265A (zh) * | 2014-12-31 | 2015-05-13 | 芜湖杨燕制药有限公司 | 一种化合物及其制备方法 |
CN104606197A (zh) * | 2014-12-31 | 2015-05-13 | 芜湖杨燕制药有限公司 | 一种化合物的抗肿瘤用途 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳-法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
CN106146515B (zh) * | 2015-04-17 | 2020-09-04 | 常州隆赛医药科技有限公司 | 新型激酶抑制剂的制备及应用 |
CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
CN108779117B (zh) * | 2015-12-27 | 2021-08-31 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
WO2017114512A1 (zh) | 2015-12-31 | 2017-07-06 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 |
US11921116B2 (en) | 2016-03-09 | 2024-03-05 | Memorial Sloan Kettering Cancer Center | Enigma and CDH18 as companion diagnostics for CDK4 inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
NZ746554A (en) | 2016-04-01 | 2023-03-31 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
ES2895419T3 (es) | 2016-04-01 | 2022-02-21 | Signal Pharm Llc | Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
KR20230162137A (ko) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
DK3500299T3 (da) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer |
US20190175598A1 (en) | 2016-08-23 | 2019-06-13 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
EP3515414B1 (en) | 2016-09-19 | 2022-11-30 | MEI Pharma, Inc. | Combination therapy |
SG11201902523UA (en) | 2016-10-20 | 2019-05-30 | Pfizer | Anti-proliferative agents for treating pah |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
JP2020502062A (ja) * | 2016-11-17 | 2020-01-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | アルキルピロロピリミジン類似体、及びその製造方法と使用方法 |
AR110400A1 (es) | 2016-12-20 | 2019-03-27 | Astrazeneca Ab | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer |
WO2018117177A1 (ja) * | 2016-12-21 | 2018-06-28 | 小野薬品工業株式会社 | Brk阻害化合物 |
US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
US11578067B2 (en) | 2017-01-30 | 2023-02-14 | Kyoto University | Compound, and method for producing regulatory T cells |
EP4218820A3 (en) | 2017-03-16 | 2023-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
BR112019026483A2 (pt) | 2017-06-16 | 2020-07-14 | Beta Pharma, Inc. | formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
US11174254B2 (en) * | 2017-09-28 | 2021-11-16 | Yangtze River Pharmaceutical Group Co., Ltd. | Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof |
EP3692041A1 (en) | 2017-10-04 | 2020-08-12 | Celgene Corporation | Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
CN111432841A (zh) | 2017-10-04 | 2020-07-17 | 细胞基因公司 | 顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的组合物和使用方法 |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3746072B1 (en) | 2018-01-29 | 2023-04-12 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
EP3746429B1 (en) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
CA3043066A1 (en) | 2018-05-14 | 2019-11-14 | Apotex Inc. | Processes for the preparation of ribociclib and intermediates thereof |
WO2019222524A1 (en) * | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Alkyl pyrrolopyrimidines as pan-tam inhibitors and their application in cancer treatment |
CN110577524B (zh) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | 一种激酶选择性抑制剂 |
CN109438447B (zh) * | 2018-09-11 | 2020-10-16 | 北京工业大学 | 5,7-二氢-6H-吡咯并[2,3-d]嘧啶-6-酮类衍生物制备方法和应用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US20220056037A1 (en) * | 2018-12-28 | 2022-02-24 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
WO2020140054A1 (en) * | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
WO2020168197A1 (en) * | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020227563A1 (en) | 2019-05-08 | 2020-11-12 | Vimalan Biosciences, Inc. | Jak inhibitors |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
EP4009967A4 (en) | 2019-08-08 | 2023-07-26 | Vimalan Biosciences, Inc. | JAK INHIBITORS |
TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
GB201911868D0 (en) * | 2019-08-19 | 2019-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US20230024521A1 (en) * | 2019-09-25 | 2023-01-26 | Vimalan Biosciences, Inc. | Jak inhibitors |
JP2022551668A (ja) | 2019-10-11 | 2022-12-12 | インサイト・コーポレイション | Cdk2阻害剤としての二環式アミン |
CN114555600B (zh) * | 2019-10-17 | 2024-03-01 | 辰欣药业股份有限公司 | 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物 |
KR20220097455A (ko) * | 2019-11-13 | 2022-07-07 | 메드샤인 디스커버리 아이엔씨. | Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 |
WO2021124106A1 (en) * | 2019-12-16 | 2021-06-24 | Lunella Biotech, Inc. | Selective cdk4/6 inhibitor cancer therapeutics |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
KR102409595B1 (ko) * | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
US11780840B2 (en) | 2020-07-02 | 2023-10-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
CZ309356B6 (cs) * | 2020-09-15 | 2022-09-28 | Ústav experimentální botaniky AV ČR, v. v. i | Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty |
CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
WO2022135360A1 (zh) * | 2020-12-21 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
EP4313987A2 (en) | 2021-04-01 | 2024-02-07 | KRKA, d.d., Novo mesto | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof |
WO2022226290A1 (en) * | 2021-04-22 | 2022-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | 2-phenylamino pyrrolopyrimidines as ack1 inhibitors |
WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
WO2023241620A1 (en) * | 2022-06-14 | 2023-12-21 | Suzhou Keen Therapeutics Co., Ltd. | Biologically active compounds and methods thereof |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05306226A (ja) * | 1992-04-27 | 1993-11-19 | Takeda Chem Ind Ltd | 慢性免疫疾患治療剤 |
MXPA04008592A (es) * | 2002-03-07 | 2004-12-06 | Hoffmann La Roche | Inhibidores de piridina biciclica y pirimidina p38 cinasa. |
EA200600372A1 (ru) | 2003-09-05 | 2006-08-25 | Ньюроджин Корпорейшн | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) |
JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | サイトカイン阻害剤 |
US7319102B1 (en) * | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
WO2005080393A1 (en) * | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1725562A1 (en) | 2004-03-05 | 2006-11-29 | Taisho Pharmaceutical Co., Ltd | Pyrrolopyrimidine derivatives |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
KR20070085286A (ko) * | 2004-10-29 | 2007-08-27 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 저해하는 바이사이클릭 피리미딘 유도체 |
US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
AU2006205851A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
JP2006241089A (ja) * | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
GB0520164D0 (en) | 2005-10-04 | 2005-11-09 | Novartis Ag | Organic compounds |
WO2007058990A2 (en) * | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
MX2008011525A (es) * | 2006-03-09 | 2008-09-18 | Pharmacopeia Inc | Inhibidores de mnk2 de 8-heteroarilpurina para el tratamiento de trastornos metabolicos. |
EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
MX2010008719A (es) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. |
-
2007
- 2007-05-23 TW TW096118407A patent/TWI398252B/zh active
- 2007-05-23 JO JOP/2007/0193A patent/JO3235B1/ar active
- 2007-05-24 NZ NZ572549A patent/NZ572549A/en unknown
- 2007-05-24 BR BRPI0712816A patent/BRPI0712816B8/pt active IP Right Grant
- 2007-05-24 AR ARP070102252A patent/AR061124A1/es active IP Right Grant
- 2007-05-24 GE GEAP200710989A patent/GEP20115283B/en unknown
- 2007-05-24 PE PE2007000646A patent/PE20080263A1/es active IP Right Grant
- 2007-05-24 CA CA2652044A patent/CA2652044C/en active Active
- 2007-05-24 US US12/302,223 patent/US8324225B2/en active Active
- 2007-05-24 KR KR1020087031411A patent/KR101466412B1/ko active IP Right Grant
- 2007-05-24 MX MX2008015076A patent/MX2008015076A/es active IP Right Grant
- 2007-05-24 CN CN2007800193572A patent/CN101594871B/zh active Active
- 2007-05-24 JP JP2009512291A patent/JP2009538341A/ja active Pending
- 2007-05-24 EA EA200802332A patent/EA016301B1/ru not_active IP Right Cessation
- 2007-05-24 WO PCT/US2007/069595 patent/WO2007140222A2/en active Application Filing
- 2007-05-24 EP EP07811927.8A patent/EP2029145B1/en active Active
- 2007-05-24 AU AU2007267645A patent/AU2007267645C1/en active Active
- 2007-05-24 PL PL07811927T patent/PL2029145T3/pl unknown
- 2007-05-24 MY MYPI20084701 patent/MY150650A/en unknown
- 2007-05-24 ME MEP-2008-766A patent/ME00486B/me unknown
- 2007-05-24 SM SM200800069T patent/SMP200800069B/it unknown
- 2007-05-24 PT PT78119278T patent/PT2029145T/pt unknown
- 2007-05-24 UA UAA200813340A patent/UA95632C2/uk unknown
- 2007-05-24 ES ES07811927.8T patent/ES2623133T3/es active Active
- 2007-05-24 SG SG2011037637A patent/SG172632A1/en unknown
- 2007-05-25 CL CL200701504A patent/CL2007001504A1/es unknown
- 2007-05-25 UY UY30369A patent/UY30369A1/es active IP Right Grant
-
2008
- 2008-11-03 IL IL195086A patent/IL195086A/en active IP Right Grant
- 2008-11-03 ZA ZA2008/09382A patent/ZA200809382B/en unknown
- 2008-11-10 CR CR10433A patent/CR10433A/es unknown
- 2008-11-21 TN TNP2008000481A patent/TNSN08481A1/en unknown
- 2008-11-24 CU CU2008000223A patent/CU23831B1/es active IP Right Grant
- 2008-11-24 GT GT200800258A patent/GT200800258A/es unknown
- 2008-11-25 HN HN2008001752A patent/HN2008001752A/es unknown
- 2008-11-26 EC EC2008008910A patent/ECSP088910A/es unknown
- 2008-12-01 MA MA31431A patent/MA30557B1/fr unknown
- 2008-12-02 NO NO20085030A patent/NO343182B1/no unknown
-
2012
- 2012-04-20 US US13/452,100 patent/US20120207763A1/en not_active Abandoned
-
2013
- 2013-01-23 JP JP2013010317A patent/JP5740417B2/ja active Active
-
2017
- 2017-04-05 AR ARP170100874A patent/AR108179A2/es unknown
- 2017-04-21 HR HRP20170631TT patent/HRP20170631T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088910A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
CR10336A (es) | Compuestos organicos y sus usos | |
UY32123A (es) | Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones | |
UY32551A (es) | Compuestos peptidomiméticos de sulfamida y usos antivirales de los mismos | |
UY32554A (es) | Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
GT200900256A (es) | 3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas | |
SV2009003235A (es) | Triazoles biciclicos como moduladores de la proteina cinasa ref. x-18476m | |
DOP2010000013A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
MX2008005853A (es) | Mezclas insecticidas sinergicas para el tratamiento de las semillas | |
BRPI0821151A2 (pt) | Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina | |
CR11430A (es) | 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus | |
HN2006037713A (es) | Compuestos utiles en terapia | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
NI201000060A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA. | |
SV2009003307A (es) | Quinazolinas para la inhibicion de pdk1 | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ECSP088922A (es) | Derivados de amino-tiazol y sus usos como agentes antibacterianos | |
DOP2006000087A (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos | |
ECSP10010389A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
GT200500310A (es) | Compuestos organicos | |
CO6280510A2 (es) | Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa | |
HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
AR060402A1 (es) | Compuestos organicos y sus usos | |
ECSP099836A (es) | Macrociclos y sus usos |